GLP1R and myocardial infarction: A recent study examined the efficacy of a newly synthesized GLP-1R agonist, compound DMB, in attenuating pathological left ventricular remodeling in a permanent coronary artery ligation mice model and suggested that increasing mitochondrial biogenesis and Parkin-associated mitophagy after MI might be a viable target for the therapeutic management of adverse cardiac remodeling [139].